cysteine and su 11248

cysteine has been researched along with su 11248 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chen, H; Fu, Y; Ge, X; Guo, H; Hu, Z; Li, M; Li, X; Meng, L; Qian, X; Shi, Z; Yin, J; Zhao, N; Zhao, X	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

1 review(s) available for cysteine and su 11248

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

1 other study(ies) available for cysteine and su 11248

Article	Year
Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma. Molecular cell, 2022, 04-07, Volume: 82, Issue:7 Topics: Carcinogenesis; Carcinoma, Papillary; Carcinoma, Renal Cell; Cysteine; Drug Resistance, Neoplasm; Fumarate Hydratase; Fumarates; Humans; Kidney Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sunitinib	2022

Article

Year

Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.

Molecular cell, 2022, 04-07, Volume: 82, Issue:7

Topics: Carcinogenesis; Carcinoma, Papillary; Carcinoma, Renal Cell; Cysteine; Drug Resistance, Neoplasm; Fumarate Hydratase; Fumarates; Humans; Kidney Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sunitinib

2022